07:43 AM EDT, 04/11/2025 (MT Newswires) -- Perspective Therapeutics ( CATX ) said Friday it has dosed the first patient in a new cohort of its phase 1/2a trial evaluating [212Pb]VMT01 as a monotherapy for melanoma patients with confirmed positive MC1R imaging scans.

This cohort includes patients with brain metastases and administers [212Pb]VMT01 at a dose of 1.5 millicuries.

The investigational therapy delivers targeted alpha-particle therapy to treat metastatic melanoma. The US Food and Drug Administration granted Fast Track Designation for [212Pb]VMT01 in September 2024.

Perspective Therapeutics ( CATX ) shares were up over 17% in recent premarket activity.

Price: 2.19, Change: +0.33, Percent Change: +17.74